Newer aminopyrimidinimino isatin analogues as non-nucleoside HIV-1 reverse transcriptase inhibitors for HIV and other opportunistic infections of AIDS: Design, synthesis and biological evaluation

Farmaco

Volumn 60, Issue 5, 2005, Pages 377-384

  Sriram, D ^a   Bal, T R ^a   Yogeeswari, P ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Anti HCV; Anti HIV; Antibacterial; Antituberculosis; Isatin

Indexed keywords

[3 [[4' AMINO 5 (3'',4'',5'' TRIMETHOXYBENZYL)PYRIMIDIN 2' YL]]IMINO] 5 METHYL 1,3 DIHYDRO 2H INDOL 2 ONE; [3 [[4' AMINO 5' (3'',4'',5'' TRIMETHOXYBENZYL)PYRIMIDIN 2' YL]]IMINO] 5 METHYL 1 [(4 CHLOROPHENYLPIPERAZINYL)METHYL] 1,3 DIHYDRO 2H INDOL 2 ONE; [3 [[4' AMINO 5' (3'',4'',5'' TRIMETHOXYBENZYL)PYRIMIDIN 2' YL]]IMINO] 5 METHYL 1 [(4 PHENYLPIPERAZINYL)METHYL] 1,3 DIHYDRO 2H INDOL 2 ONE; ANTIINFECTIVE AGENT; CARBOXYLIC ACID DERIVATIVE; ISATIN DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ARTICLE; BACTERIAL INFECTION; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; HEPATITIS C VIRUS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPPORTUNISTIC INFECTION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; DRUG DESIGN; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; ISATIN; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PYRIMIDINONES; VIRUS REPLICATION;

EID: 19444378215     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.farmac.2005.03.005     Document Type: Article

References (15)

1. D.L. Bowen, H.C. Hane, and A.C. Fauci Immunopathogenesis of the acquired immunodeficiency syndrome Ann. Intern. Med. 103 1985 704 709
2. A. Di Bisceglie, and C. Hepatitis Lancet 351 1998 351 355
3. R.R. Rosado, P.M. Olmeda, G.J. Samaniego, and V. Soriano Management of hepatitis C in HIV-infected persons Antiviral Res. 52 2001 189 198
4. D. Sriram, and P. Yogeeswari Towards the design and development of agents with broad spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS Curr. Med. Chem. 10 2003 1909 1915
5. E. De Clercq Perspectives of non-nucleoside reverse transcriptase inhibitors in the therapy of HIV-1 infection Farmaco 54 1999 26 45
6. E. De Clercq What can be expected from non-nucleoside reverse transcriptase inhibitors in the treatment of human immuno deficiency virus type-1 infections? Med. Virol. 6 1996 97 117
7. Tripos Alchemy Alchemy 32 Version 2.0 2000 Copyright 1997, Tripos Inc. St. Louis, MO, USA
8. S.N. Pandeya, D. Sriram, E. De Clercq, C. Pannecouque, and M. Witrouw Anti-HIV activity of some Mannich bases of isatin derivatives Ind. J. Pharm. Sci. 60 1998 207 212
9. S.N. Pandeya, P. Yogeeswari, D. Sriram, E. De Clercq, C. Pannecouque, and M. Witrouw Synthesis and screening for anti-HIV activity of some N-Mannich bases of isatin derivatives Chemotherapy 45 1999 192 196
10. J. Balzarini, P.M.J. Perez, S.A. Felix, M.J. Camarasa, I.C. Batharst, and P.J. Barr Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-d-ribofuranosyl]-3'-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide)thymine (TSAO-T) J. Biol. Chem. 267 1992 11831 11838
11. C.A. Garcia, M. Micklatcher, J.A. Turpin, T.L. Stup, K. Watson, and R.W. Buckheit Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors J. Med. Chem. 42 1999 4861 4874
12. J.T. Guo, V.V. Bichkow, and C. Seeger Effect of alpha interferon on the hepatitis C virus replicon J. Virol. 75 2001 8516 8523
13. D. Sriram, K. Jyothimallika, and P. Yogeeswari Synthesis of tetrahydro-2H-[1,3,5] thiadiazine-5-(4-pyridylcarboxamido)-2-thione with antitubercular activity Sci. Pharm. 72 2004 35 41
14. S.N. Pandeya, and D. Sriram Synthesis and screening for antibacterial activity of Schiff's and Mannich bases of Isatin and its derivatives Acta Pharm. Turc. 40 1998 33 38
15. S.N. Pandeya, D. Sriram, G. Nath, and E. De Clercq Synthesis, antibacterial, antifungal and anti-HIV activities of norfloxacin Mannich bases Eur. J. Med. Chem. 35 2000 249 265